PROTECTING PATIENTS STARTS WITH A STRONG RECOMMENDATION FROM YOU

What you say matters

To communicate the importance of vaccination with SHINGRIX, follow a simple 3-step plan:

Step 1 icon

Educate patients on shingles1,2

Explain that shingles is a painful, blistering rash that can last 7 to 10 days and may lead to complications.* Starting at 50 years old, shingles risk sharply increases.

Step 2 icon

Make the risk of shingles relatable

Personalize your recommendation by using pronouns such as “you” along with connecting to the patient’s age group. Share an experience of the impact shingles has had on your patients and the importance of vaccination.

Step 3 icon

Recommend SHINGRIX

Use actionable language to round out your recommendation so it’s clear to the patient that your recommendation is coming from a place of protection. Set expectations by outlining potential vaccine side effects and creating a vaccination plan with your patients. 

  • *

    SHINGRIX is not indicated for the prevention of herpes zoster-related complications.3

 

Your strong recommendation can positively influence their vaccination decision4

Establish a plan with your patients to vaccinate in office or at pharmacy:

For patients 50-64 years old

The best time to vaccinate is during their office visit

  • According to the Centers for Disease Control and Prevention, when patients receive a vaccine recommendation and are offered the vaccine at the same time, they are more likely to get vaccinated4

For patients ≥65 years old

Talk to your patients about SHINGRIX when discussing other health considerations

  • Provide a prescription for SHINGRIX
  • Have your staff help patients schedule their SHINGRIX vaccine at their pharmacy by using the Vaccine Scheduler at
ScheduleSHINGRIX.com

SHINGRIX is $0

for most patients ≥50 years old5,6,†

 

†Coverage and cost may vary and are subject to change without notice.
Reimbursement decisions are made by individual insurance plans.

SEE COST AND COVERAGE INFORMATION
SHINGRIX Strong Recommendation Guide

Share the SHINGRIX Strong Recommendation Discussion Guide with others in your practice

DOWNLOAD RESOURCE
Download PDF Root Path

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Shingles symptoms and complications. Centers for Disease Control and Prevention. April 19, 2024. Accessed May 21, 2024. https://www.cdc.gov/shingles/signs-symptoms/index.html
  2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
  3. Prescribing Information for SHINGRIX.
  4. Adult immunization standards. Centers for Disease Control and Prevention. August 9, 2024. Accessed August 28, 2024. https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.html
  5. Data on file, GSK.
  6. Kirchhoff SM. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022; 1-3. Accessed March 1, 2024. https://crsreports.congress.gov/product/pdf/IF/IF12203

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET